Development and evaluation of new bioactive compounds with prospective pharmacological or environmental applications, namely:
Chelating agents for: a) decorporation of specific excessive/misplaced hard metal ions (Fe/Al); solid supported chelators for environmental metal decontamination (e.g. actinides in aqueous fluids); b) metal(III) complexes for delivering radionuclides or paramagnetic probes to specific target site diseases aimed at diagnosis purposes (eg 67/68Ga, Gd);
Inhibitors of metalloenzymes enzymes containing Zinc at the active site (eg MMPs, HDAC and CAs), which are involved in cancer or inflammatory diseases;
Polyfunctional anti-neurodegenerative drugs or multi-target-directed ligands (eg inhibitors of AChE with additional pharmacological/biochemical properties, such as anti-(beta-amyloid) aggregation, anti-oxidant and metal-chelating properties) for the delay/prevention of brain disorders, such as Alzheimer´s disease.